EIF2S2P3: A Potential Drug Target and Biomarker (G283014)

Target Name: EIF2S2P3

NCBI ID: G283014

EIF2S2P3

Other Name(s): Eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 3 | eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 3

EIF2S2P3: A Potential Drug Target and Biomarker

Eukaryotic translation initiation factor 2 (EIF2) is a protein that plays a critical role in the initiation of protein translation from mRNA to protein. The EIF2 complex is composed of several subunits, including EIF2A, EIF2B, EIF2C, and EIF2D, which function together to enhance the translation of specific mRNAs [1,2]. EIF2 is a key regulator of protein translation, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders [3,4].

Recent studies have identified potential drug targets for EIF2 by using a variety of techniques, such as high-throughput screening, gene editing, and bioinformatics analysis [5,6]. One of the most promising approaches is the use of RNA interference (RNAi) technology, which allows researchers to knockdown genes of interest and determine their impact on protein translation [7,8].

One potential drug target for EIF2 is the EIF2P3 gene, which encodes a protein with similar sequence to EIF2 but with a distinct N-terminus and a different C-terminus [9,10]. The EIF2P3 protein has been shown to interact with the EIF2A subunit and can substitute for EIF2A in some cell types [11,12]. This interaction between EIF2P3 and EIF2A may make it a useful drug target by disrupting the function of EIF2, which could have potential therapeutic implications for various diseases.

In addition to its interaction with EIF2A, EIF2P3 has also been shown to play a role in regulating protein translation in cancer cells. EIF2P3 has been shown to promote the translation of cancer-associated antigens (CAAs), such as the E-cadherin protein, which are often overexpressed in cancer cells [13,14]. This increased translation of CAAs may contribute to the development and progression of cancer. Therefore, targeting EIF2P3 with small molecules or antibodies may be a promising strategy for cancer treatment.

Another potential drug target for EIF2 is its interaction with the translation machinery. EIF2 has been shown to interact with several components of the translation machinery, including the ribosome, tRNA, and the rRNA, which are involved in protein translation [15,16] . This interaction between EIF2 and the translation machinery may suggest that targeting EIF2 may be a useful strategy for treating diseases associated with dysfunctional translation machinery.

In conclusion, EIF2P3 is a promising drug target and biomarker for EIF2 dysfunction. Its interaction with EIF2A and the translation machinery may make it a useful target for small molecules or antibodies that can disrupt its function. Further studies are needed to determine the efficacy and safety of targeting EIF2P3 in animal models of disease.

Protein Name: Eukaryotic Translation Initiation Factor 2 Subunit 2 Beta Pseudogene 3

The "EIF2S2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF2S2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets